CN105078951A - Application of mandelic acid to inhibiting propionibacterium acne - Google Patents
Application of mandelic acid to inhibiting propionibacterium acne Download PDFInfo
- Publication number
- CN105078951A CN105078951A CN201410203435.6A CN201410203435A CN105078951A CN 105078951 A CN105078951 A CN 105078951A CN 201410203435 A CN201410203435 A CN 201410203435A CN 105078951 A CN105078951 A CN 105078951A
- Authority
- CN
- China
- Prior art keywords
- mandelic acid
- propiobacterium
- skin
- suppressing
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Cosmetics (AREA)
Abstract
The invention provides application of mandelic acid to inhibiting propionibacterium acne. The application includes that the mandelic acid with the weight percentage concentration of 10%-30% is applied to the skin of a patient, so that hyperplasia of the propionibacterium acne can be inhibited; a pH (potential of hydrogen) value of the mandelic acid is higher than 3.5.
Description
Technical field
The invention provides a kind of mandelic acid (Mandelicacid) and suppress the purposes in Propiobacterium, referring in particular to and bestowing pH value is that the mandelic acid of 3.5 is on skin, to suppress the application of skin thalline hypertrophy, therefore, mandelic acid can be further used as antibacterial cosmetic compositions or medical composition.
Background technology
Skin is the natural cover for defense of human body isolation external environment, and skin under normal conditions and non-sterile, but has hundreds of normal flora (normalflora) growth at skin surface.Research finds, the bacterial species in human skin is different along with time variations; Some antibacterial survives on the human skin throughout the year, and they are mainly divided into four classes such as staphylococcus, streptococcus, propionibacterium and corynebacterium, and remaining antibacterial then lives away from home on human skin momently.These antibacterials stem from the air, object etc. of human peripheral's environment as contact, and it depends on the natural product that skin produces to support one's family, such as with the horny layer that skin comes off (dead bark) and sebum for nutritional labeling, thus existence and breeding.They also participate in skin cell metabolism, have the effect of immunity and self-cleaning.Generally speaking, as long as skin is without wound and the non-hyperplasia of antibacterial, normal flora causes dermopathic probability little.But except normal flora, skin also may exist some interim floras, these interim floras are be made up of the pathogenic bacteria be present in surrounding equally, but likely cause dermatosis, and are called as pathogenic bacterium.Therefore, how to maintain the balance of skin surface bacterial growth, and avoid antibacterial hyperplasia, just become an important topic.
Mandelic acid (Mandelicacid), have another name called mandelic acid, formal name used at school is Alpha-hydroxy phenylacetic acid (2-Hydroxy-2-phenylaceticacid), due to the similar antibiotic of its chemical structural formula, good antibacterial effect is had for escherichia coli and streptococcus, therefore early stage mandelic acid is mainly applied in the problem for the treatment of of urinary tract infections, and is used as oral antibiotic.Until the skin specialist Dr.JamesE.Fulton of famous American just starts mandelic acid to be applied to dermatology beauty treatment fields, change the use of skin as face.Mandelic acid belongs to lipotropy fruit acid, and infiltration horny layer ability is comparatively strong, and gentleness does not stimulate, not easily produce side effect that general fruit acid changes skin as red and swollen, burn and incrustation etc., therefore change skin composition than other all more effective.
Propiobacterium (Propionibacteriumacnes) is a kind of growth phase to typical gram-positive anaerobic bacterium (shaft-like) slowly, and dermatosis acne are closely bound up.The dermatosis that general treatment Propiobacterium is caused, mainly by antibiotic or take two or more merging Drug therapys, such as antibiotic merges benzoyl peroxide (benzoylperoxide, BPO), BPO merging external A acid or antibiotic merging external A acid are treated, but excessively use antibiotic, antibiotic resistant or other side effect may be caused.In sum, current mandelic acid has many application on medical cosmetology field, and but not concrete research confirms its impact for Propiobacterium.
Summary of the invention
Now, namely inventor is in view of the medicine of above-mentioned existing suppression Propiobacterium implements still have many places defect when using in reality, so rely on tireless spirit, and under passing through the help of its abundant Professional knowledge and practical experience for many years, and the medicine of existing suppression Propiobacterium is improved, and grind accordingly and create the present invention.
Main purpose of the present invention is for providing a kind of mandelic acid suppressing the purposes in Propiobacterium, it refers to that bestowing pH value is that the mandelic acid of 3.5 is on skin, to suppress the application of skin thalline hypertrophy, therefore, mandelic acid can be further used as antibacterial cosmetic compositions or medical composition.
In order to reach above-mentioned enforcement object, the invention provides a kind of mandelic acid and suppressing the purposes in Propiobacterium, its be bestow an effective dose mandelic acid on skin, to suppress Propiobacterium hypertrophy; Wherein, the pH value of mandelic acid is 3.5, and effective dose can be such as 10%-30% mandelic acid.
In one embodiment of this invention, mandelic acid also has the ability suppressing escherichia coli, bacillus pyocyaneus and staphylococcus aureus.
Present invention further teaches a kind of cosmetic compositions containing mandelic acid and suppressing the purposes in Propiobacterium, its be bestow an effective dose cosmetic compositions on skin, to suppress Propiobacterium hypertrophy; Wherein cosmetic compositions is made up of the sterilized water of the mandelic acid of concentration expressed in percentage by weight 10%-30%, the 1,3 butylene glycol of 0.5%-1.5% and residuals weight percentage concentration, and the pH value of mandelic acid is more than 3.5, and pH value is preferably 3.5.
Therefore, mandelic acid can be used as and suppresses Propiobacterium, the cosmetic compositions of bacillus pyocyaneus and staphylococcus aureus or medical composition, to reduce the chance that skin is infected by bacterial.
Accompanying drawing explanation
Fig. 1 a to be pH be 1.9 mandelic acid suppressing the paper ingots diffusion test result figure in Propiobacterium;
Fig. 1 b to be pH be 3.5 mandelic acid suppressing the paper ingots diffusion test result figure in Propiobacterium;
Fig. 2 is that mandelic acid is suppressing the bacteriostatic test result figure in Propiobacterium;
Fig. 3 is that mandelic acid is suppressing the paper ingots diffusion test result figure in escherichia coli;
Fig. 4 is that mandelic acid is suppressing the bacteriostatic test result figure in escherichia coli;
Fig. 5 is that mandelic acid is suppressing the paper ingots diffusion test result figure in bacillus pyocyaneus;
Fig. 6 is that mandelic acid is suppressing the bacteriostatic test result figure in bacillus pyocyaneus;
Fig. 7 is that mandelic acid is suppressing the paper ingots diffusion test result figure in staphylococcus aureus;
Fig. 8 is that mandelic acid is suppressing the bacteriostatic test result figure in staphylococcus aureus.
Detailed description of the invention
Advantage in object of the present invention and structure function thereof, by according to the structure shown in following figure, coordinates specific embodiment to be explained, makes auditor can have more deep and concrete understanding to the present invention.
The invention provides a kind of mandelic acid (Mandelicacid, MA) purposes in Propiobacterium is being suppressed, its be bestow a concentration expressed in percentage by weight be the mandelic acid of 10%-30% on skin, to suppress Propiobacterium (Propionibacteriumacne) hypertrophy; Wherein, the pH value of mandelic acid is more than 3.5, and pH value is preferably 3.5.
Moreover, present invention provides a kind of cosmetic compositions containing mandelic acid and suppressing the purposes in Propiobacterium, its be bestow an effective dose cosmetic compositions on skin, to suppress Propiobacterium hypertrophy; Wherein cosmetic compositions is made up of the sterilized water of the mandelic acid of concentration expressed in percentage by weight 10%-30%, the 1,3 butylene glycol of 0.5%-1.5% and residuals weight percentage concentration, and the pH value of mandelic acid is more than 3.5, and pH value is preferably 3.5.
In one embodiment of this invention, mandelic acid also can suppress escherichia coli (Escherichiacoli), bacillus pyocyaneus (Pseudomonasaeruginosa) and staphylococcus aureus (Staphylococcusaureus).
In addition, by following specific embodiment, can prove that the present invention can the scope of practical application further, but can not be interpreted as any type of restriction is carried out to scope of the present invention.
< Pharmaceutical formulations >
Mandelic acid in the present embodiment buys from Science Court, Guangde Chemical Co., Ltd..Take the powder 1g of mandelic acid, and add the 1,3 butylene glycol of 1mL sterilized water and 50 μ L, being heated to 90 DEG C of maintenances subsequently makes it dissolve in about 10 minutes, and this concentration is 100%, and by pH furnishing 1.9 or 3.5, filter, in order to carry out following test with the filter membrane of 0.22 μm again.
< paper ingots diffusion test >
Get 100 μ L1 × 10
8the Propiobacterium of cfu/mL, escherichia coli, bacillus pyocyaneus and staphylococcus aureus bacterium liquid are on solid medium, 8mm paper ingots are positioned over after utilizing triangular glass rod uniform application, instill the mandelic acid of the different pH value of 40 μ L or commercially available antibiotic (streptomycine-penicillin, SP), put and cultivate after 24 hours at 37 DEG C, calculate paper ingots antibacterial circle diameter size (diameterofinhibitionzone), the bacteriostasis of assessment mandelic acid; Wherein, antibiotic, escherichia coli, bacillus pyocyaneus and staphylococcus aureus are used to be used as positive control group.
< bacteriostatic test >
Get 90 μ L variable concentrations mandelic acid diluent (pH3.5) in 96 porose discs (96-wellplate), get 10 μ L different vaccination original bacteria liquids (5 × 10
6cfu/mL) add in each hole (well), after 37 DEG C are cultivated 24 hours, under 600nm wavelength, survey light absorption value.
Mandelic acid is for the result suppressing Propiobacterium (P.acnes) to be tested:
Refer to Fig. 1 a, paper ingots diffusion test result shows, pH is that the antibacterial circle diameter size of the mandelic acid (Mandelicacid, MA) of the variable concentrations (10%, 20% and 30%) of 1.9 is respectively 20.9mm, 26.9mm and 30.8mm (as shown in table 1); Consult Fig. 1 b, paper ingots diffusion test result shows, pH is the antibacterial circle diameter size of the mandelic acid of the variable concentrations (10%, 20% and 30%) of 3.5 is 23.1mm, 25.9mm and 26.1mm (as shown in table 2), represent pH be 1.9 and pH be 3.5 variable concentrations mandelic acid all have and suppress Propiobacterium effect.In bacteriostatic test, be utilize the light absorption value of OD600nm to judge that mandelic acid suppresses the ability of Propiobacterium growth, to assess the inhibition of mandelic acid for Propiobacterium; As shown in Figure 2, no matter be the mandelic acid of 10%, 20% and 30%, its bacteriostasis for Propiobacterium (antimicrobialactivity) all can reach more than 60-80% to result, shows that mandelic acid has the effect suppressing Propiobacterium admirably.
Table 1
| Propiobacterium suppresses loop diameter size (mm) | |
| Control group | - |
| Antibiotic (SP) | 35.2±0.6 |
| Mandelic acid (pH1.9,10%) | 20.9±0.3 |
| Mandelic acid (pH1.9,20%) | 26.9±0.1 |
| Mandelic acid (pH1.9,30%) | 30.8±0.2 |
Table 2
| Propiobacterium suppresses loop diameter size (mm) | |
| Control group | - |
| Antibiotic (SP) | 35.2±0.9 |
| Mandelic acid (pH3.5,10%) | 23.1±1.0 |
| Mandelic acid (pH3.5,20%) | 25.9±0.6 |
| Mandelic acid (pH3.5,30%) | 26.1±0.7 |
Mandelic acid is for the result suppressing escherichia coli (E.coli) to be tested:
Refer to Fig. 3, paper ingots diffusion test result shows, pH be 1.9 mandelic acid be 27.8mm for the diameter of escherichia coli inhibition zone, be better than antibiotic 25.8mm, and pH be 3.5 mandelic acid effect (23.8mm) also with effects of antibiotics close to (as shown in table 3).In addition, in bacteriostatic test, adding pH is that the mandelic acid of the variable concentrations (10%, 20% and 30%) of 3.5 acts on escherichia coli, utilizes the light absorption value of OD600nm to judge that mandelic acid suppresses the ability of Escherichia coli Growth; As shown in Figure 4, no matter be the mandelic acid of 10%, 20% and 30%, have good fungistatic effect for escherichia coli, its bacteriostasis all can reach more than 90% to result.
Table 3
| Escherichia coli suppress loop diameter size (mm) | |
| Control group | - |
| Antibiotic (SP) | 25.8 |
| Mandelic acid (pH1.9) | 27.8 |
| Mandelic acid (pH3.5) | 23.8 |
Mandelic acid is for the result suppressing bacillus pyocyaneus (P.aeruginosa) to be tested:
Refer to Fig. 5, paper ingots diffusion test result shows, pH be 1.9 mandelic acid be 37.8mm for the diameter of bacillus pyocyaneus inhibition zone, be better than antibiotic 31.8mm, and pH be the mandelic acid of 3.5 effect (23.8mm) also with effects of antibiotics close to (as shown in table 4).In addition, in bacteriostatic test, adding pH is that the mandelic acid of the variable concentrations (10%, 20% and 30%) of 3.5 acts on bacillus pyocyaneus, utilizes the light absorption value of OD600nm to judge that mandelic acid suppresses the ability of bacillus pyocyaneus growth; As shown in Figure 6, no matter be the mandelic acid of 10%, 20% and 30%, have good fungistatic effect for bacillus pyocyaneus, its bacteriostasis all can reach about 80% to result.
Table 4
| Bacillus pyocyaneus suppresses loop diameter size (mm) | |
| Control group | - |
| Antibiotic (SP) | 31.8 |
| Mandelic acid (pH1.9) | 37.8 |
| Mandelic acid (pH3.5) | 23.8 |
Mandelic acid is for the result suppressing staphylococcus aureus (S.aureus) to be tested:
Refer to Fig. 7, paper ingots diffusion test result shows, pH be 1.9 and pH be that the antibacterial circle diameter of the mandelic acid of 3.5 is respectively 23.8mm and 19.8mm, with antibiotic 31.8mm close to (as shown in table 5).In addition, in bacteriostatic test, adding pH is that the mandelic acid of the variable concentrations (10%, 20% and 30%) of 3.5 acts on staphylococcus aureus, utilizes the light absorption value of OD600nm to judge that mandelic acid suppresses the ability of staphylococcus aureus growth; As shown in Figure 8, no matter be the mandelic acid of 10%, 20% and 30%, have good fungistatic effect for staphylococcus aureus, its bacteriostasis can reach about 74% to result.
Table 5
| Staphylococcus aureus suppresses loop diameter size (mm) | |
| Control group | - |
| Antibiotic (SP) | 31.8 |
| Mandelic acid (pH1.9) | 23.8 |
| Mandelic acid (pH3.5) | 19.8 |
In sum, when mandelic acid of the present invention is applied to cosmetic compositions or medical composition, its form can include but not limited to water preparation, Emulsion, unguentum, powder, whitening agent, the cosmetics of light speckle agent or above-mentioned combination in any or pharmaceuticals.
It should be noted that amygdalate pH-value of the present invention meets the regulation of legal pH value more than 3.5, although use pH to be less than the growth of the mandelic acid Triclosan bacillus of 3.5 (such as pH1.9); But, the problem such as skin irritation, redness may be caused when bestowing human body skin.In addition, when the concentration that pH is the mandelic acid of 3.5 is less than 10%, it cannot reach the effect suppressing Propiobacterium growth preferably; If concentration is greater than 30%, though the growth of Triclosan bacillus, it also may cause the problems such as user skin irritation, redness, allergy.Therefore, pH is that the concentration of the mandelic acid of 3.5 is preferably 10%-30% in the present invention.
From above-mentioned implementation, compared with prior art, the present invention has the following advantages in the present invention:
1. the present invention utilizes paper ingots diffusion test and bacteriostatic test, and concrete confirmation mandelic acid has the ability suppressing Propiobacterium growth.The mandelic acid that pH-value meets more than regulation pH3.5 can avoid the reactions such as skin irritation, redness, allergy to produce.
2. according to purposes of the present invention, mandelic acid can be used as the constituent of cosmetics or pharmaceuticals, in order to suppress Propiobacterium, and then reduces skin acne bacillus infection.
Claims (6)
1. mandelic acid is suppressing the purposes in Propiobacterium, its be bestow a concentration expressed in percentage by weight be the mandelic acid of 10%-30% on skin, to suppress Propiobacterium hypertrophy; Wherein the pH value of this mandelic acid is more than 3.5.
2. purposes as claimed in claim 1, wherein, the pH value of described mandelic acid is 3.5.
3. purposes as claimed in claim 1, its be bestow a concentration expressed in percentage by weight be the mandelic acid of 10%-30% on skin, to suppress escherichia coli, bacillus pyocyaneus and staphylococcus aureus further.
4. the cosmetic compositions containing mandelic acid is suppressing the purposes in Propiobacterium, its be bestow an effective dose cosmetic compositions on skin, to suppress Propiobacterium hypertrophy; Wherein, described cosmetic compositions is the mandelic acid of 10%-30%, the 1,3 butylene glycol of 0.5%-1.5% by concentration expressed in percentage by weight, and the sterilized water of residuals weight percentage concentration formed, and the pH value of this mandelic acid is more than 3.5.
5. purposes as claimed in claim 4, wherein, the pH value of described mandelic acid is 3.5.
6. purposes as claimed in claim 4, its be bestow an effective dose cosmetic compositions on skin, to suppress escherichia coli, bacillus pyocyaneus and staphylococcus aureus further.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410203435.6A CN105078951A (en) | 2014-05-14 | 2014-05-14 | Application of mandelic acid to inhibiting propionibacterium acne |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410203435.6A CN105078951A (en) | 2014-05-14 | 2014-05-14 | Application of mandelic acid to inhibiting propionibacterium acne |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105078951A true CN105078951A (en) | 2015-11-25 |
Family
ID=54560889
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410203435.6A Pending CN105078951A (en) | 2014-05-14 | 2014-05-14 | Application of mandelic acid to inhibiting propionibacterium acne |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105078951A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105708750A (en) * | 2016-01-05 | 2016-06-29 | 李志诚 | Plant composition for improving keratosis pilaris as well as preparation method and applications of plant composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006132515A1 (en) * | 2005-06-09 | 2006-12-14 | Inha-Industry Partnership Institute | Agent for the treatment of vaginitis containing mandelic acid as an active ingredient |
| CN1946369A (en) * | 2004-04-27 | 2007-04-11 | 拜埃尔斯多尔夫股份公司 | Transparent cosmetic or dermatological formulation |
| US20130177618A1 (en) * | 2010-10-23 | 2013-07-11 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
-
2014
- 2014-05-14 CN CN201410203435.6A patent/CN105078951A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1946369A (en) * | 2004-04-27 | 2007-04-11 | 拜埃尔斯多尔夫股份公司 | Transparent cosmetic or dermatological formulation |
| WO2006132515A1 (en) * | 2005-06-09 | 2006-12-14 | Inha-Industry Partnership Institute | Agent for the treatment of vaginitis containing mandelic acid as an active ingredient |
| US20130177618A1 (en) * | 2010-10-23 | 2013-07-11 | Joel Schlessinger | Topical base and active agent-containing compositions, and methods for improving and treating skin |
Non-Patent Citations (3)
| Title |
|---|
| MARK B. TAYLOR: "Summary of Mandelic Acid for the Improvement of Skin conditions", 《COSMETIC DERMATOLOGY》 * |
| 何彬等: "药物中间体扁桃酸的合成", 《大众科技》 * |
| 雷鹏程: "《皮肤病性病中西医结合治疗学》", 31 January 2013 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105708750A (en) * | 2016-01-05 | 2016-06-29 | 李志诚 | Plant composition for improving keratosis pilaris as well as preparation method and applications of plant composition |
| CN105708750B (en) * | 2016-01-05 | 2018-10-09 | 李志诚 | Plant composition and its preparation method and application for improving hair week angling |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sen et al. | Biofilm management in wound care | |
| Akram et al. | A combination of silver nanoparticles and visible blue light enhances the antibacterial efficacy of ineffective antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) | |
| Zhao et al. | Biofilms and inflammation in chronic wounds | |
| Wei et al. | Chronic wound biofilms: diagnosis and therapeutic strategies | |
| Pietrocola et al. | Evaluation of the antibacterial activity of a new ozonized olive oil against oral and periodontal pathogens | |
| CN104274490B (en) | Bactericidal composition including source of silver ions and menthol and application thereof | |
| Gelmetti | Local antibiotics in dermatology | |
| Evren et al. | In vitro effects on biofilm viability and antibacterial and antiadherent activities of silymarin | |
| Uzer Celik et al. | Antimicrobial activity of different disinfectants against cariogenic microorganisms | |
| Nagoba et al. | A simple and effective approach for the treatment of diabetic foot ulcers with different Wagner grades | |
| Osmanov et al. | The antiseptic Miramistin: a review of its comparative in vitro and clinical activity | |
| Almeida et al. | Antimicrobial activity of the essential oil of Cymbopogon citratus (DC) Stapf. on Staphylococcus spp., Streptococcus mutans and Candida spp. | |
| Lang et al. | Tyrothricin–an underrated agent for the treatment of bacterial skin infections and superficial wounds? | |
| Selçuk et al. | Comparison of the antibacterial effect of silver sulfadiazine 1%, mupirocin 2%, Acticoat and octenidine dihydrochloride in a full-thickness rat burn model contaminated with multi drug resistant Acinetobacter baumannii | |
| CN103083472A (en) | Nano silver anti-inflammatory gel for treating gynecologic inflammation and preparation method thereof | |
| CN109077945A (en) | Combined bacteriostat with lysozyme for cosmetics | |
| Gobin et al. | A combination of the natural molecules gallic acid and carvacrol eradicates P. aeruginosa and S. aureus mature biofilms | |
| US20060264411A1 (en) | Control of biofilm formation | |
| Safadi et al. | The products of probiotic bacteria effectively treat persistent Enterococcus faecalis biofilms | |
| Le Bourgot et al. | Effects of short chain fructo-oligosaccharides on selected skin bacteria | |
| Elnagdy et al. | Local Oral Delivery Agents with Anti-Biofilm Properties for the Treatment of Periodontitis and Peri-Implantitis. A Narrative Review | |
| Nagoba et al. | Treatment of lepromatous ulcers using citric acid as a sole antimicrobial agent | |
| JP2019509353A (en) | Treatment of skin conditions and diseases associated with microbial biofilms | |
| WO2013191565A1 (en) | Antimicrobial composition and its method of use | |
| CN105078951A (en) | Application of mandelic acid to inhibiting propionibacterium acne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151125 |
|
| WD01 | Invention patent application deemed withdrawn after publication |